The BAMBAM project aims at reintegrating the display manufacturing industry in Europe while enabling the era of the low energy µLED for this application. Microprinting of electrical and optical structures and active LEDs pixels (µLED on CMOS) are the solutions implemented in BAMBAM to get rid of the Thin Film Transistor (TFT) arrays controlling LCD and OLED displays; all of them being manufactured in Asia in dedicated expensive, enormous and energy-intensive plants. The new BAMBAM technology relies on the unique active µLEDs on silicon by ALEDIA, where each µLED has its own CMOS driver that can be connected to a low cost substrate by printing of micron scale bussing on any substrate. Following micro-printing by University of Stuttgart of the XTPL's ink, containing Qustom dots color conversion components, on the µLED of Aledia, and their transfer on a low cost substrates by XDC and Xceleprint, the contact ink is micro-printed to connect the active pixel elements to the substrates. The 2 types of display demonstrators, manufactured with this technology, are then adjusted and operated by Barco to achieve the best picture quality at the low energy consumption of the µLED for TV and video walls. The solution is compatible with a high pixel count and low pixel size on flexible substrates. Manufacturing displays in Europe, with a low energy consumption along the life cycle of the product, on low end flexible substrates and low cost, is being prepared by Aledia in its new european manufacturing-line, which is under construction with the help of partners from all over Europe.

Cancer in the Upper Aerodigestive Tract (UADT) is still among the leading cancer types worldwide, with both incidence rate and mortality rate constantly rising. Treatment of these diseases is by Ear-Nose-Throat (ENT) surgeons, operating with incomplete knowledge of the tumor geometry, under non-ergonomic conditions and with limited precision on fragile cancerous tissue. AIRCARE will bring clinical practice in diagnosis and surgical treatment to the next level, by introducing advanced AI and robotic technology into the clinical workflow. For diagnosis, AIRCARE will enable real-time on-the-spot AI-powered optical/electric biopsies, helping to optimize a patient-specific surgical approach. For surgery, AIRCARE will provide a more controlled and ergonomic setting. Novel robotic stabilizing and controlling tools will further allow manipulation of tissue and removal of cancer with unprecedented levels of precision. A newly developed intuitive 3D visualization will simplify the understanding of the complex surgical scene. Aside from increase of safety, quality and efficiency of the surgical procedure, also less experienced surgeons may become able to perform complex image guided treatments. Within this innovation action, our European partners spanning universities, research centers, industry and 3 hospitals, will join forces across disciplines to advance promising research prototypes into two advanced integrated systems: one for diagnosis, one for surgery, thus supporting clinicians from the detection and diagnosis of UADT diseases until their surgical treatment. Within the framework of the project, the superiority of AIRCARE technology will be demonstrated in real operational environments through three clinical studies. By doing so, we aim to demonstrate the benefits of AI and robotics to healthcare professionals and UADT patients and put the seeds to translate this technology into the next standard of care for improved clinical outcomes.